Nanobiotix S.A. NBTX
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- +18.14%
- 1 year
- +26.11%
- Market cap
- 1.39B
- Revenue (ttm)
- 11.51M
- EPS (ttm)
- -1.27
- Shares out
- 50.95M
- Forward P/E
- -162.85
- YTD return
- +18.14%
- 1-year return
- +26.11%
- 50-day average
- 29.72
- 200-day average
- 34.41
- Volume
- 178.00K
- Avg volume
- 147.23K
- Open
- 29.68
- Previous close
- 26.90
- Day's range
- 27.18 – 29.68
- 52-week range
- 19.14 – 57.14
- Beta
- 0.54
- Price target
- 53.32 (+95.2%)
- Earnings date
- Apr 27, 2027
Key statistics
- Enterprise value
- 1.36B
- Price / sales
- 120.95
- Revenue growth
- -79.20%
- Free cash flow
- -32.78M
- Total cash
- 110.89M
- Total debt
- 106.61M
- Short % of float
- 0.45%
Fundamental scorecard
6 of 25 checks passed on NBTX’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Analyst view
- Target (low)
- 29.55
- Target (mean)
- 53.32
- Target (high)
- 68.61
- Strong buy0
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Apr 27, 2027
Expected Apr 27, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 27, 2027 | Dec 30, 2026 | 0.05703 | — | — | — |
| Sep 29, 2026 | Jun 30, 2026 | -0.48457 | -0.7981 | -0.31 | -64.70% |
| Mar 31, 2026 | Dec 31, 2025 | 0.3039 | -0.45809 | -0.76 | -250.74% |
| Sep 30, 2025 | Jun 30, 2025 | -0.24704 | -0.13367 | +0.11 | +45.89% |
| Apr 2, 2025 | Dec 31, 2024 | -0.62 | -1.01 | -0.39 | -63.46% |
| Nov 12, 2024 | Jun 30, 2024 | -0.5117 | -0.49906 | +0.01 | +2.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 4, 2026 | Leerink Partners | main | Outperform | Outperform |
| May 1, 2026 | UBS | main | Neutral | Neutral |
| Apr 2, 2026 | Guggenheim | main | Buy | Buy |
| Feb 6, 2026 | Guggenheim | main | Buy | Buy |
| Apr 4, 2025 | Guggenheim | main | Buy | Buy |
| Aug 28, 2024 | Guggenheim | init | — | Buy |
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- nanobiotix.com
News
Voting Rights and Shares Capital of the Company
Kosmos Energy Posts Downbeat Q3 Results, Joins Once Upon A Farm And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday
Your note
Sign in to keep a note on NBTX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Johnson & Johnson | 11.03% | 5,623,816 | 153.61M | Sep 29, 2026 |
| Citadel Advisors Llc | 0.70% | 357,861 | 9.77M | Sep 29, 2026 |
| Woodline Partners LP | 0.49% | 251,408 | 6.87M | Sep 29, 2026 |
| Jane Street Group, LLC | 0.06% | 32,877 | 898.03K | Sep 29, 2026 |
| HRT Financial LP | 0.05% | 26,529 | 724.64K | Sep 29, 2026 |
| Dorsey Wright & Associates | 0.03% | 16,546 | 451.95K | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.01% | 4,489 | 122.62K | Sep 29, 2026 |
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.00% | 1,048 | 28.63K | Jul 30, 2026 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.00% | 1,649 | 45.04K | Aug 30, 2026 |
